Pamela J Hodul
Affiliation: H. Lee Moffitt Cancer Center and Research Institute
- Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?Pamela J Hodul
Gastrointestinal Tumor Program, Departmentsof Surgery, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer Control 15:314-21. 2008..This paper discusses whether aggressive surgical intervention is indicated for PNETs and investigates what prognostic factors may assist in predicting which patients with invasive disease will benefit most from surgical intervention...
- Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinomaEric A Mellon
Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
Acta Oncol 54:979-85. 2015..Limited data are available to guide neoadjuvant treatment of borderline resectable (BRPC) and locally advanced (LAPC) pancreatic cancer...
- Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classificationsJonathan R Strosberg
Department of GI Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
Ann Surg 256:321-5. 2012....
- Silencing of the candidate tumor suppressor gene solute carrier family 5 member 8 (SLC5A8) in human pancreatic cancerJong Y Park
Division of Cancer Prevention and Control, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Pancreas 36:e32-9. 2008....
- Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experienceJoyce Wong
Department of Gastrointestinal Oncology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA
Am J Surg 208:775-80. 2014..Staging for pancreatic neuroendocrine tumors (PNET) considers tumor size and lymph node (LN) status; however, correlation with survival remains unclear...
- Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well toleratedMichael D Chuong
Department of Radiation Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
Int J Radiat Oncol Biol Phys 86:516-22. 2013....
- Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic CancerOmar M Rashid
Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Ann Surg Oncol 23:1371-9. 2016..This study investigated the outcomes of the clinical pathway at the author's institution, which consists of neoadjuvant gemcitabine, docetaxel, capecitabine, and stereotactic radiotherapy followed by surgery...
- Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutationDerek H Jones
Department of Anatomic Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA
Cancer Control 22:102-8. 2015..As with cases of sporadic gastrointestinal stromal tumor (GIST), familial GIST syndrome arises from mutations in KIT or PDGFRA. Only a few dozen such families have been described in the literature...
- Vitamin E δ-tocotrienol induces p27(Kip1)-dependent cell-cycle arrest in pancreatic cancer cells via an E2F-1-dependent mechanismPamela J Hodul
Department of Gastrointestinal Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States of America
PLoS ONE 8:e52526. 2013....
- Outcomes following resection of pancreatic adenocarcinoma: 20-year experience at a single institutionJames F Helm
Gastrointestinal Tumor Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
Cancer Control 15:288-94. 2008....
- Octreotide does not prevent postoperative pancreatic fistula or mortality following PancreaticoduodenectomySean P Barnett
Department of Surgery and Biostatistics, Loyola Stritch School of Medicine, Maywood, Illinois, USA
Am Surg 70:222-6; discussion 227. 2004..026). Octreotide did not reduce pancreatic fistula, other complications, or mortality. Octreotide may contribute cardiac morbidity. Octreotide cannot be recommended to prevent mortality or postoperative complications after PD...
- Zero mortality after 152 consecutive pancreaticoduodenectomies with pancreaticogastrostomyGerard V Aranha
Section of Surgical Oncology, Hines VA Hospital, Maywood, IL 60153, USA
J Am Coll Surg 197:223-31; discussion 231-2. 2003..In all of these series, the pancreatic remnant was anastomosed to the jejunum...